File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Termination of second trimester pregnancy with gemeprost and misoprostol: A randomized double-blind placebo-controlled trial

TitleTermination of second trimester pregnancy with gemeprost and misoprostol: A randomized double-blind placebo-controlled trial
Authors
Keywordsgemeprost
oral misoprostol
second trimester termination
Issue Date1996
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraception
Citation
Contraception, 1996, v. 54 n. 1, p. 23-25 How to Cite?
AbstractA prospective randomized double-blind placebo-controlled trial was conducted in 70 subjects to determine whether pre-treatment with misoprostol could facilitate termination of second trimester pregnancy by gemeprost. The women received either 400 μg oral misoprostol or placebo tablets 12 hours before the administration of vaginal pessary of gemeprost 1 mg every 3 hours. There were no significant differences in induction-abortion interval and the amount of gemeprost required between the misoprostol and the placebo group. There was no significant difference in the incidence of side effects or analgesic requirement between the two groups. We conclude that oral misoprostol is not useful in facilitating termination of second trimester pregnancy by gemeprost. | In Hong Kong, 70 healthy women aged 16-40 years at the gestational age of 14-20 weeks who requested legal termination of pregnancy were randomly allocated to receive either 400 mg misoprostol or a placebo (vitamin B6) 12 hours before initial administration of intravaginal gemeprost pessary (1 mg) every three hours. This double-blind study aimed to determine whether pretreatment with oral misoprostol can improve the efficacy of intravaginal gemeprost pessary to effect induced abortion. The two groups responded essentially the same in terms of the incidence of nausea, vomiting, dizziness, fatigue, breast tenderness, or lower abdominal pain during the interval between misoprostol administration and gemeprost administration. Similarly, side effects and analgesic requirements did not differ significantly. The complete abortion rate was not significantly different between the two groups (62.9% for misoprostol and 68.6% for placebo). Even though the induction-abortion interval was shorter and the amount of gemeprost required was smaller in the misoprostol group than the placebo group (27.3 vs. 28.2 hours and 4.9 vs. 5.7 mg, respectively), the differences were not significant (p = 0.0863 and 0.0957, respectively). These findings suggest that oral misoprostol does not facilitate termination of second trimester pregnancy by intravaginal gemeprost pessary.
Persistent Identifierhttp://hdl.handle.net/10722/87170
ISSN
2015 Impact Factor: 2.788
2015 SCImago Journal Rankings: 1.557
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, KSen_HK
dc.contributor.authorNgai, CSWen_HK
dc.contributor.authorChan, KSen_HK
dc.contributor.authorTang, LCHen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-09-06T09:26:14Z-
dc.date.available2010-09-06T09:26:14Z-
dc.date.issued1996en_HK
dc.identifier.citationContraception, 1996, v. 54 n. 1, p. 23-25en_HK
dc.identifier.issn0010-7824en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87170-
dc.description.abstractA prospective randomized double-blind placebo-controlled trial was conducted in 70 subjects to determine whether pre-treatment with misoprostol could facilitate termination of second trimester pregnancy by gemeprost. The women received either 400 μg oral misoprostol or placebo tablets 12 hours before the administration of vaginal pessary of gemeprost 1 mg every 3 hours. There were no significant differences in induction-abortion interval and the amount of gemeprost required between the misoprostol and the placebo group. There was no significant difference in the incidence of side effects or analgesic requirement between the two groups. We conclude that oral misoprostol is not useful in facilitating termination of second trimester pregnancy by gemeprost. | In Hong Kong, 70 healthy women aged 16-40 years at the gestational age of 14-20 weeks who requested legal termination of pregnancy were randomly allocated to receive either 400 mg misoprostol or a placebo (vitamin B6) 12 hours before initial administration of intravaginal gemeprost pessary (1 mg) every three hours. This double-blind study aimed to determine whether pretreatment with oral misoprostol can improve the efficacy of intravaginal gemeprost pessary to effect induced abortion. The two groups responded essentially the same in terms of the incidence of nausea, vomiting, dizziness, fatigue, breast tenderness, or lower abdominal pain during the interval between misoprostol administration and gemeprost administration. Similarly, side effects and analgesic requirements did not differ significantly. The complete abortion rate was not significantly different between the two groups (62.9% for misoprostol and 68.6% for placebo). Even though the induction-abortion interval was shorter and the amount of gemeprost required was smaller in the misoprostol group than the placebo group (27.3 vs. 28.2 hours and 4.9 vs. 5.7 mg, respectively), the differences were not significant (p = 0.0863 and 0.0957, respectively). These findings suggest that oral misoprostol does not facilitate termination of second trimester pregnancy by intravaginal gemeprost pessary.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraceptionen_HK
dc.relation.ispartofContraceptionen_HK
dc.rightsContraception. Copyright © Elsevier Inc.en_HK
dc.subjectgemeprosten_HK
dc.subjectoral misoprostolen_HK
dc.subjectsecond trimester terminationen_HK
dc.titleTermination of second trimester pregnancy with gemeprost and misoprostol: A randomized double-blind placebo-controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0010-7824&volume=54&spage=3pp&epage=&date=1996&atitle=Termination+of+second+trimester+pregnancy+with+gemeprost+and+misoprostol:+a+randomized+double-blind+placebo-controlled+trialen_HK
dc.identifier.emailTang, LCH: lchtang@hku.hken_HK
dc.identifier.emailHo, PC: pcho@hku.hken_HK
dc.identifier.authorityTang, LCH=rp01756en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/0010-7824(96)00115-1en_HK
dc.identifier.pmid8804804en_HK
dc.identifier.scopuseid_2-s2.0-0030200140en_HK
dc.identifier.hkuros14353en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030200140&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume54en_HK
dc.identifier.issue1en_HK
dc.identifier.spage23en_HK
dc.identifier.epage25en_HK
dc.identifier.isiWOS:A1996UU21000005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, KS=36341790700en_HK
dc.identifier.scopusauthoridNgai, CSW=6603676357en_HK
dc.identifier.scopusauthoridChan, KS=25031061700en_HK
dc.identifier.scopusauthoridTang, LCH=7402081111en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats